Clinical Gastroenterology and Hepatology
Volume 1, Issue 4 , Pages 322-327, July 2003

An evidence-based approach to clinical practice guidelines: diagnosis and treatment of irritable bowel syndrome1

  • Philip Schoenfeld

      Affiliations

    • Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    • Veterans Affairs Center for Excellence in Health Services Research, Ann Arbor, Michigan, USA
    • Corresponding Author InformationAddress requests for reprints to: Philip Schoenfeld, M.D., MSEd, MSc (Epi), Division of Gastroenterology (111D), VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, Michigan 48105, USA. fax: (734) 761-5260.
    • Dr. Schoenfeld is a consultant for Novartis Pharmaceuticals Corporation, Proctor and Gamble, and AstraZeneca LP. Dr. Schoenfeld is on the Speakers Bureau for AstraZeneca LP, Wyeth Laboratories, TAP Pharmaceuticals, Novartis Pharmaceuticals Corporation, Boehringer Ingleheim, and Merck. Dr. Chey is a consultant for Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals, and AstraZeneca LP. Dr. Chey has received research support from Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals, AstraZeneca LP, and Janssen. Dr. Chey is on the Speakers Bureau for Novartis Pharmaceutical Corporation, AstraZeneca LP, TAP Pharmaceuticals, and Janssen.
    • ,
  • William D Chey

      Affiliations

    • Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    • Dr. Schoenfeld is a consultant for Novartis Pharmaceuticals Corporation, Proctor and Gamble, and AstraZeneca LP. Dr. Schoenfeld is on the Speakers Bureau for AstraZeneca LP, Wyeth Laboratories, TAP Pharmaceuticals, Novartis Pharmaceuticals Corporation, Boehringer Ingleheim, and Merck. Dr. Chey is a consultant for Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals, and AstraZeneca LP. Dr. Chey has received research support from Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals, AstraZeneca LP, and Janssen. Dr. Chey is on the Speakers Bureau for Novartis Pharmaceutical Corporation, AstraZeneca LP, TAP Pharmaceuticals, and Janssen.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    • PII: S1542-3565(03)00139-3

    Clinical Gastroenterology and Hepatology
    Volume 1, Issue 4 , Pages 322-327, July 2003